Norwood, Mass. — January 5, 2026 — Leads & Copy — Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview at the 2026 Annual J.P. Morgan Healthcare Conference, scheduled for January 12-15, 2026, in San Francisco, CA.
The presentation is scheduled for January 15, 2026, at 8:15 a.m. PST/11:15 a.m. EST. The conference format includes the presentation and one-on-one investor meetings. A webcast link is available by clicking here.
Corbus Pharmaceuticals Holdings, Inc. is focused on bringing innovative scientific approaches to well-understood biological pathways to help people defeat serious illnesses. Its pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells; and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity.
Corbus is headquartered in Norwood, Massachusetts.
Investor Contacts:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com
Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
Source: Corbus Pharmaceuticals
